Added Section 5.1.6 Extended Treatment to clarify this phase of treatment, which permits participants who have completed the maximum duration of study treatment to have an extended treatment up to an additional 24 weeks. Table 9.5-3: Pharmacokinetic and Immunogenicity Sampling Schedule for BMS-986226 (Parts C1 and C2)Grade 3/4 hypersensitivity reaction sampling time poi nt was added for pharmacokinetic (PK) and anti drug antibody (ADA) sampling in Parts C1 and C2.Added PK and ADA sampling for Grade 3/4 hypersensitivity to better evaluate any drug-related AEs, infusion reactions, or hypersensitivity reactions. Table 9.5-1: Pharmacokinetic and Immunogenicity Sampling Schedule for BMS-986226, Table 9.5-2: Pharmacokinetic and Immunogenicity Post-DLT Period Sampling Schedule for BMS-986226, Table 9.5-3: Pharmacokinetic and Immunogenicity Sampling Schedule for BMS-986226 (Parts C1 and C2); Table 9.5-4: Additional and Retreatment Cycles Pharmacokinetic and Immunogenicity Sampling Schedule for BMS-986226, Dose delay sample collection timepoints were added for PK and ADA sampling in the event that a dose is delayed.Updated the PK and ADA sampling tables to align with procedural requirements described in the body of the protocol. Table 2-3: Follow-up Procedural Outline (CA021002)Tumor assessments were added for all participants in survival follow-up until beginning a new anti-cancer therapy.Updated the study procedural outline table to align with the requirements for tumor assessments in Section 5.1.3.3: Response Follow-up.